FDA approves Anktiva for non-muscle-invasive bladder cancer – The Cancer Letter
FDA has approved ImmunityBio’s Anktiva (N-803, or nogapendekin alfa inbakicept-pmln) plus Bacillus Calmette-Guérin for the treatment of patients with BCG-unresponsive non-muscle-invasive bladder cancer with carcinoma in situ, with or without papillary tumors. To access this subscriber-only content please log in or renew your subscription.Looking for IP Login? Our IP Login system is now automatic. If […]